Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Coherus BioSciences Inc (NASDAQ:CHRS)

20.45
BATS BZX Real-Time Price
As of 1:50pm ET
 -1.40 / -6.41%
Today’s Change
14.00
Today|||52-Week Range
31.98
-27.35%
Year-to-Date
AbbVie's Humira Loses Patent in Coherus' Petitions
May 18 / GuruFocus News - Paid Partner Content
AbbVie Stock Lower on Humira Patent Ruling
May 17 / TheStreet.com - Paid Partner Content
AbbVie Down on Humira Patent Loss: Is More Damage in Store?
May 18 / Zacks.com - Paid Partner Content
Are Options Traders Betting on a Big Move in COHERUS BIOSCIENCES (CHRS) Stock?
May 12 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close21.85
Today’s open21.75
Day’s range20.30 - 21.75
Volume11,278
Average volume (3 months)538,484
Market cap$1.1B
Dividend yield--
Data as of 1:50pm ET, 05/24/2017

Growth & Valuation

Earnings growth (last year)+49.42%
Earnings growth (this year)-71.78%
Earnings growth (next 5 years)--
Revenue growth (last year)+532.82%
P/E ratioNM
Price/Sales6.21
Price/Book48.76

Competitors

 Today’s
change
Today’s
% change
MNTAMomenta Pharmaceutic...+0.48+3.23%
XLRNAcceleron Pharma Inc+0.51+2.01%
EPZMEpizyme Inc-0.05-0.30%
RDUSRadius Health Inc-0.15-0.40%
Data as of 1:54pm ET, 05/24/2017

Financials

Next reporting dateAugust 14, 2017
EPS forecast (this quarter)-$1.25
Annual revenue (last year)$190.1M
Annual profit (last year)-$127.3M
Net profit margin-66.98%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Denny M. Lanfear
Chief Financial Officer
Jean-Frédéric Viret
Corporate headquarters
Redwood City, California

Forecasts